Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy
Published: 13 February 2023| Version 1 | DOI: 10.17632/67v3272wt7.1
Contributor:
Description
Supplemental Materials for the manuscript: Influence of melanoma type on incidence and downstream implications of cutaneous immune-related adverse events in the setting of immune checkpoint inhibitor therapy
Files
Institutions
Massachusetts General Hospital
Categories
Dermatology, Immunotherapy, Adverse Event, Melanoma, Immune Checkpoint Inhibitor